Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Emerging treatments for advanced cholangiocarcinoma: Addressing the knowledge gap.
Authors
Elizabeth J Heller
i3 Health, Rochelle Park, NJ
Elizabeth J Heller , Keira A Smith , Kristin L Wright , Sarah L Williams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
DOI
10.1200/JCO.2022.40.4_suppl.484
Abstract #
484
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
First Author: Milind M. Javle
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements.
First Author: Mitesh J. Borad
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
First Author: James J. Harding
Poster
2022 ASCO Annual Meeting
FGFR2 fusion detection in plasma: A new era in the clinical monitoring of iCCA.
First Author: Alberto Gonzalez-Medina